Generated by All in One SEO v4.9.10, this is an llms.txt file, used by LLMs to index the site.

# Pharmx

Pharmx is the first choice for pharmacy ordering, trusted by 99% of pharmacies across ANZ. We connect pharmacies and suppliers—and all those in between—to help them do more, in less time.

## Sitemaps

- [XML Sitemap](https://pharmx.com.au/sitemap.xml): Contains all public & indexable URLs for this website.

## Pages

- [Homepage](https://pharmx.com.au/) - Pharmx is the first choice for pharmacy ordering, trusted by 99% of pharmacies across ANZ. We connect pharmacies and suppliers—and all those in between—to help them do more, in less time.
- [Team](https://pharmx.com.au/team/) - Bringing together expertise from health, technology and business - we’re on a mission to build a better future for healthcare. Meet the team!
- [For Suppliers](https://pharmx.com.au/for-suppliers/) - Home / For Suppliers Helping pharmacy suppliers connect, sell and scale Connect with the 99% of Australian pharmacies already on our platform. With streamlined, integrated solutions, you can reach more customers, showcase your products, drive loyalty, and uncover deep business insights. Get started Your full-service partner for pharmacy trade From order management, payments and business
- [Marketplace](https://pharmx.com.au/marketplace/) - Stocking up just got simple. Shop 80%+ of your range in one place, with live stock availability, personalised pricing and more.
- [For Pharmacies](https://pharmx.com.au/for-pharmacies/) - Home / For Pharmacies Get back to putting customers first Spend less time behind the screen and more in front of customers, with reliable, time-saving tech used by 99% of Australian pharmacies. Request demo Reliable, time-saving tech Access the largest network of suppliers across ANZ through Pharmx’s multi-channel ordering platform, including our Gateway and Marketplace
- [Resources](https://pharmx.com.au/resources/) - Explore expert insights, real-world stories and practical resources to help you stay ahead in today’s dynamic pharmacy industry.
- [Privacy Policy](https://pharmx.com.au/privacy-policy/) - Home / Privacy Policy Privacy policy Pharmx Technologies Limited (ACN 000 091 305) and the entities it controls (“Pharmx”, “we”, “us” or “our”) is an ASX-listed technology company providing electronic data interchange (EDI), marketplace and analytics solutions to the Australian and New Zealand pharmacy industries. This Privacy Policy explains how we collect, hold, use and
- [Marketplace Incentive Terms & Conditions (May26)](https://pharmx.com.au/marketplace-incentive-terms-conditions-may26/) - Home / Marketplace Incentive Terms & Conditions (May26) Terms & Conditions Promotion Name: Rewards Recognition Incentive Promotion Period: 20 May 2026 – 17 August 2026 1. Eligibility This promotion is open to pharmacies located in Australia, who are registered as Pharmx Pharmacy Portal customers (Customers). Customers must hold an active and verified Pharmx account connected
- [Investor Centre](https://pharmx.com.au/investor-centre/) - Home / Investor Centre At the centre of ANZ’s pharmacy industry Used by 99% of Australian pharmacies and with an expanding footprint in New Zealand, Pharmx is a central to the ANZ pharmacy industry. Request demo Vital technology infrastructure Pharmx (ASX: PHX) technology solutions support and connect pharmacy, supplier, brand, government, and technology partners—including via
- [Marketplace Incentive Terms & Conditions (April26)](https://pharmx.com.au/marketplace-incentive-terms-conditions-april26/) - Home / Marketplace Incentive Terms & Conditions (April26) Terms & Conditions Promotion Name: Pharmx Marketplace 90 Day First Purchase Incentive ProgramPromotion Period: Rolling 90-day program commencing from a Participant’s first qualifying purchase on the Pharmx Marketplace. First purchase must be made after 1 April 2026 and before 1 July 2026. 1. Eligibility This promotion is open to pharmacies located in Australia, who are
- [Pharmacy Portal StockView](https://pharmx.com.au/stock/) - Instant visibility across 120,000+ products from hundreds of suppliers, all in one place. StockView - new from Pharmx.
- [Supplier Portal](https://pharmx.com.au/supplier-portal/) - Pharmx connects you to 99% of pharmacies across Australia and New Zealand—so you can trade faster, grow your distribution, and manage everything in one place.
- [Terms & Conditions](https://pharmx.com.au/terms-of-use/) - Home / Terms & Conditions Terms & conditions 1. Introduction In these terms and conditions (the Terms and Conditions), “we”, “our”, “us” or “PharmX” means PharmX Pty Ltd. Please read the Terms and Conditions carefully as they apply to your use of the internet site www.pharmx.com.au or any other PharmX owned and operated internet site,
- [Supplier Directory](https://pharmx.com.au/supplier-directory/) - Home / Supplier Directory
- [Request Demo Supplier Portal](https://pharmx.com.au/request-demo-supplier-portal/) - Request a demo, and we’ll walk you through the features of our Supplier Portal in detail, answer your questions, and tailor a solution for you.
- [Register Interest Paid Marketing](https://pharmx.com.au/register-interest-paid-marketing/) - We deliver a range of paid marketing initiatives to help our supplier partners expand their reach across our extensive pharmacy network.
- [Refer a Supplier](https://pharmx.com.au/refer-a-supplier/) - Whilst our brand-new Supplier Portal is built for suppliers, there’s plenty in it for pharmacies too. Refer your supplier today.
- [Pharmx Media Pre-Registration](https://pharmx.com.au/pharmx-media-pre-registration/) - Interested in Pharmx Media solutions? Register your interest and we will get back to you shortly.
- [Pharmx Media Enquiry](https://pharmx.com.au/pharmx-media-enquiry/) - Interested in Pharmx Media solutions? Register your interest and we will get back to you shortly.
- [Pharmx Marketplace Launch Offer Terms & Conditions](https://pharmx.com.au/pharmx-marketplace-launch-offer-terms-conditions/) - Home / Pharmx Marketplace Launch Offer Terms & Conditions Terms & Conditions Promotion Name: Pharmx Marketplace Incentive Program Promotion Period: From 11th November 2025 to 9th February 2026 1.Eligibility This promotion is open to all registered Pharmx pharmacy customers located in Australia. Participants must be aged 18 years or older. Participants must have an active
- [Pharmx Analytics Enquiry](https://pharmx.com.au/pharmx-analytics-enquiry/) - Make confident decisions with trusted insights from ANZ’s most comprehensive pharmacy supply data. Enquire today.
- [Pharmacy Portal](https://pharmx.com.au/pharmacy-portal/) - The new Pharmacy Portal helps you get the most from the Pharmx Gateway — explore suppliers, track spend, view order history, and manage connections with ease.
- [Partners](https://pharmx.com.au/partners/) - Home / Partners Join the largest network for bigger impact Be part of the industry’s leading pharmacy network that brings together pharmacy, supplier, government, and technology partners. Pharmx brings expanded opportunities for all partners to deliver enhanced value across the industry. Join Pharmx today Unlock new growth opportunities As a PharmX partner, you’ll gain access
- [Marketplace Live Demos](https://pharmx.com.au/marketplace-live-demos/) - Join us to celebrate the launch of the new Pharmx Marketplace — a faster, simpler, and smarter way to manage your pharmacy ordering.
- [Marketplace Incentive Terms & Conditions (Feb-May26)](https://pharmx.com.au/marketplace-incentive-terms-conditions-feb-may26/) - Home / Marketplace Incentive Terms & Conditions (Feb-May26) Terms & Conditions Promotion Name: Pharmx Marketplace Incentive Program (2) Promotion Period: 19 February 2026 – 19 May 2026 1. Eligibility This promotion is open to pharmacies located in Australia, who are registered as Pharmx Pharmacy Portal customers (Customers) Customers must hold an active and verified Pharmx account connected to the Pharmx
- [Enterprise Solutions Enquiry](https://pharmx.com.au/enterprise-solutions-enquiry/) - Contact the Enterprise Team to discuss how you can benefit from our enterprise-grade ERP integration – built for complex, high-volume environments.
- [Enterprise Solutions](https://pharmx.com.au/enterprise-solutions/) - With 99% pharmacy coverage, our enterprise-grade ERP integration is built for complex, high-volume retail environments.
- [Benefit with PharmX](https://pharmx.com.au/benefit-with-pharmx/) - Home / Benefit with PharmX Benefit With PharmX Did you know that e-invoicing can cut the costs of manual ordering and invoicing by up to two-thirds? Call To Action Button Goes Here How E-Invoicing Works These cost benefits result from the fact that electronic ordering and invoicing is faster and more accurate than manual options
- [About Us](https://pharmx.com.au/about-us/) - Home / About Us Tech you can trust, support you can count on Pharmx is at the heart of the pharmacy industry. As the most trusted and reliable technology partner for ordering and analytics, we leverage our scale and expertise to underpin a better healthcare system for everyone. Contact us Industry connection, reimagined Pharmx brings
- [Analytics](https://pharmx.com.au/analytics/) - Make confident decisions with trusted insights from ANZ’s most comprehensive pharmacy supply data. Custom solutions that make an impact.
- [Contact Us](https://pharmx.com.au/contact-us/) - Home / Contact Us

## Resources

- [Vaccination trends in focus as Australia approaches flu season](https://pharmx.com.au/resource/vaccination-trends-in-focus-as-australia-approaches-flu-season/) - As we head into the 2026 flu season, data points to a steady decline in vaccination uptake across the country since Covid-19, bringing renewed attention to the importance of accessible immunisation services.¹ Childhood immunisation coverage remains relatively high overall, with around 91.5% of one-year olds and 89.6% of two-year-olds fully vaccinated, yet this sits below
- [This June, let's talk men's health](https://pharmx.com.au/resource/this-june-lets-talk-mens-health/) - June is Men's Health Month in Australia and this year we're encouraging every man to take one small but important step: start the conversation. Men's Health Week runs from 15–21 June 2026, shining a light on the physical and mental wellbeing of men and boys across the country.¹ The statistics behind the campaign are sobering.
- [Carrying the weight: Pharmacy burnout and the quiet cost of being first in line](https://pharmx.com.au/resource/carrying-the-weight-pharmacy-burnout-and-the-quiet-cost-of-being-first-in-line/) - Australia is in the middle of a burnout crisis. It spans industries, job levels and demographics. But within it, community pharmacy sits in a position few other professions share: absorbing the pressure of a stressed population while managing its own. Burnout is no longer a healthcare-specific problem. Bupa reported that 70% of working Australians
- [Supplier Spotlight: Advancing Antimicrobial Stewardship with Leukomed® Sorbact®](https://pharmx.com.au/resource/supplier-spotlight-advancing-antimicrobial-stewardship-with-leukomed-sorbact/) - The following is a contributed article from Essity, shared by Pharmx as part of our ongoing Supplier Spotlight series. Antimicrobial resistance (AMR) continues to challenge healthcare systems worldwide, affecting patient outcomes, increasing hospital stays, and placing pressure on antimicrobial stewardship (AMS) efforts. For pharmacists and healthcare professionals, the focus is shifting from simply treating infections
- [The rise of the informed patient](https://pharmx.com.au/resource/the-rise-of-the-informed-patient/) - Australians are taking a more active role in managing their health. From wearable devices and health apps to online resources and digital tools, consumers have access to more health information than ever before. As a result, patients are increasingly researching conditions, exploring treatment options and seeking preventative health advice before engaging with healthcare providers. Research
- [The Unglamorous Side of AI: Better Stock, Less Admin](https://pharmx.com.au/resource/the-unglamorous-side-of-ai-better-stock-less-admin/) - When people talk about AI in healthcare, the conversation tends to jump straight to the dramatic stuff, AI reading scans to catch cancer earlier, chatbots triaging symptoms, robots assisting surgeons. It's exciting, and it's real. But across Australia's health sector, some of the most consequential AI adoption isn't happening in the consult room or the
- [The Guild's 10-year plans puts community pharmacies at the forefront of community care](https://pharmx.com.au/resource/the-guilds-10-year-plans-puts-community-pharmacies-at-the-forefront-of-community-care/) - Community pharmacies across Australia are set to play an increasingly central role in the nation's primary healthcare system, following the release of the Pharmacy Guild of Australia's new 10-year strategic plan, Towards 20351. Unveiled at the Guild's Parliamentary Dinner earlier this month, the plan sets a clear vision for the future of community pharmacy. It
- [The International Pharmacy Federation on the sustainable use of AI within Pharmacy](https://pharmx.com.au/resource/the-international-pharmacy-federation-on-the-sustainable-use-of-ai-within-pharmacy/) - The International Pharmaceutical Federation (FIP) has released a new global policy statement advocating for the ethical, evidence-based, and sustainable use of artificial intelligence in pharmacy. The document arrives at a critical moment, as AI continues to expand into health care delivery, supply chain optimisation, and clinical support. The policy outlines a vision in which AI
- [Pharmaceutical Defence Limited issues alert over children's dispensing requests](https://pharmx.com.au/resource/pharmaceutical-defence-limited-issues-alert-over-childrens-dispensing-requests/) - Pharmaceutical Defence Limited (PDL) has issued an important alert urging pharmacists to exercise heightened care when handling prescriptions and over-the-counter requests for children. A recent annual review has revealed that children are involved in around 9 per cent of all incident reports received by PDL1. PDL Professional Officers point out that this figure may reflect
- [Australia’s healthcare system is facing increasing pressure to deliver better outcomes](https://pharmx.com.au/resource/australias-healthcare-system-is-facing-increasing-pressure-to-deliver-better-outcomes/) - Australia's health system is under pressure from rising demand, growing costs, and changing expectations. Traditional output-based models, focused on activity rather than outcomes—are falling short in delivering sustainable, high-value care1. Value-based healthcare (VBHC) is gaining momentum, focusing on outcomes that matter to patients, cost efficiency, provider experience, equity, and population health. Health Research and Education
- [FDA updates warnings on HRT drugs and sparks debate](https://pharmx.com.au/resource/fda-updates-warnings-on-hrt-drugs-and-sparks-debate/) - This month in a landmark decision in the U.S., the Food and Drugs Administration (FDA) announced it will remove the black box warnings on Menopausal Hormone Replacement Therapy (MHT) products. MHT (also known as HRT) products are often used to help manage side effects of menopause, including hot flashes, night sweats and vaginal dryness. The
- [PBS pricing reform puts the spotlight on digital and operational efficiency in pharmacy](https://pharmx.com.au/resource/pbs-pricing-reform-puts-the-spotlight-on-digital-and-operational-efficiency-in-pharmacy/) - The reduction in the maximum Pharmaceutical Benefits Scheme (PBS) co-payment for general patients to $25, effective from 1 January 2026, is an important step forward in medicine affordability and patient adherence¹. However, beyond the consumer impact, it represents an important shift in how community pharmacies need to operate. Set against earlier structural changes such as
- [Pharmacy’s biggest edge in 2026 isn’t scope. It’s access.](https://pharmx.com.au/resource/pharmacys-biggest-edge-in-2026-isnt-scope-its-access/) - Community pharmacy is often framed as an expanding clinical player. But the 2026 Community Pharmacy Industry Insights Report points to something more fundamental driving its growth: access¹. Australians visited pharmacies around 440 million times in 2024, or roughly 18 visits per person¹. With more than 6,000 locations nationwide and hundreds of communities relying on pharmacy
- [Pharmacy is not general retail: why specialised technology matters for consumer health brands](https://pharmx.com.au/resource/pharmacy-is-not-general-retail-why-specialised-technology-matters-for-consumer-health-brands/) - Pharmacy retail is often grouped under the all encompassing banner of general retail. It has a front of store sales, merchandising cycles and promotional campaigns. But structurally, operationally, and regulatorily, pharmacy is fundamentally different. And the numbers reinforce why that distinction matters. Australia's retail pharmacy sector is valued at approximately $26.5 billion in 2026. ¹
- [Victoria’s pill move transforms community pharmacy roles](https://pharmx.com.au/resource/victorias-pill-move-transforms-community-pharmacy-roles/) - The move to allow pharmacists to supply the contraceptive pill without a GP prescription signals a broader shift in Australian healthcare. Community pharmacies are becoming primary care gateways. In Victoria, the state government has announced plans to allow trained pharmacists to provide the oral contraceptive pill without a traditional prescription. The reform has been widely
- [Appointment of Chief Product Officer](https://pharmx.com.au/resource/appointment-of-chief-product-officer/)
- [How to upload a CSV on Marketplace](https://pharmx.com.au/resource/how-to-upload-a-csv-on-marketplace/) - Need to place a big order? This 2-min walkthrough shows you how to upload your entire order onto Pharmx Marketplace in seconds. You'll see how to: Export your order as a CSV, with just two required columns (pde_code and quantity) Upload the file and let Marketplace match your products automatically Review matched items, pricing and
- [Cleansing Notice](https://pharmx.com.au/resource/cleansing-notice-3/)
- [Application for quotation of securities - PHX](https://pharmx.com.au/resource/application-for-quotation-of-securities-phx-4/)
- [Sigma Healthcare 10% strategic holding now complete](https://pharmx.com.au/resource/sigma-healthcare-10-strategic-holding-now-complete/)
- [Pharmx Renews National NDSS Agreement](https://pharmx.com.au/resource/pharmx-renews-national-ndss-agreement/)
- [Appointment of Chief Revenue Officer](https://pharmx.com.au/resource/appointment-of-chief-revenue-officer/)
- [Supporting Sigma's NZ distribution centre](https://pharmx.com.au/resource/supporting-sigmas-nz-distribution-centre/) - ASX Announce_20260629_SIG NZ Announcement
- [Webinar | See what's new on Pharmx Marketplace](https://pharmx.com.au/resource/webinar-see-whats-new-on-pharmx-marketplace/) - Pharmx Marketplace just got better, and we want to show you how. This webinar features: A run-through of how to use Marketplace to order from over 50,000 products Stock availability shown upfront, cutting incomplete orders in half* Exclusive supplier deals all in one place Bulk ordering across multiple suppliers in minutes, with CSV/PDE search and
- [Notice of Chief Revenue Officer Appointment](https://pharmx.com.au/resource/notice-of-chief-revenue-officer-appointment/)
- [Notice of Investor Presentation](https://pharmx.com.au/resource/notice-of-investor-presentation/)
- [Pharmx Planet MicroCap Interview with Tom Culver | June 2026](https://pharmx.com.au/resource/pharmx-planet-microcap-interview-with-tom-culver-june-2026/) - In this interview, Pharmx CEO Tom Culver sits down with Planet MicroCap to discuss Pharmx's strategic position in the pharmacy trade infrastructure, growth plans, and solutions like e-commerce and data analytics.
- [Q3 Investor Update FY2026](https://pharmx.com.au/resource/q3-investor-update-fy2026/)
- [Pharmx Key Messaging](https://pharmx.com.au/resource/announcement-kit/) - Let your pharmacy customers know you are available to order on the Pharmx Marketplace. Use the ready-made messaging and assets below across your website, EDMs and digital channels. Key messages We have prepared simple, ready-to-use content that explains what the Pharmx Marketplace is and why it matters. You can use this content as-is, or tailor
- [Pharmx social media assets](https://pharmx.com.au/resource/supplier-toolkit-social-assets/) - At Pharmx, we believe in empowering our suppliers to maximise their sales potential. By leveraging your customer networks and using our suite of powerful assets and templates, you can drive growth, improve visibility and increase customer loyalty. Social media templates We've set up a range of easy-to-use social media templates to let your customers know
- [Pharmx 'About us' Flyer](https://pharmx.com.au/resource/pharmx-about-us-flyer/) - Download our flyer to access an overview of Pharmx, designed to help pharmacies quickly understand the value of ordering, managing suppliers and accessing stock through one integrated platform. It can be used by suppliers as a simple, ready-to-share resource to support conversations with pharmacy customers. Whether you’re introducing Pharmx, reinforcing key benefits, or including it
- [Marketing Packages](https://pharmx.com.au/resource/marketing-packages/) - Our Pharmx Marketing Packages help suppliers increase visibility and connect directly with pharmacies across Australia’s largest pharmacy network. Designed to support product launches, promotional campaigns and long-term brand growth, these packages combine targeted email communications, in-platform placements, digital advertising and social media promotion to maximise reach and engagement. Suppliers can choose from 3, 6 or
- [Initial Director's Interest Notice - M Conway](https://pharmx.com.au/resource/initial-directors-interest-notice-m-conway/)
- [Director Appointment](https://pharmx.com.au/resource/director-appointment-2/)
- [Becoming a substantial holder](https://pharmx.com.au/resource/becoming-a-substantial-holder/)
- [Cleansing Notice](https://pharmx.com.au/resource/cleansing-notice-2/)
- [Application for quotation of securities - PHX](https://pharmx.com.au/resource/application-for-quotation-of-securities-phx-3/)
- [Pharmx H1 FY26 Results Presentation](https://pharmx.com.au/resource/pharmx-h1-fy26-results-presentation/) - Pharmx has released our H1 FY26 Results Presentation, highlighting continued revenue growth and strong business momentum. CEO Tom Culver and CFO Zoe Hillier shared key updates, including a new strategic alliance with Sigma Healthcare, new partners, Marketplace performance and key milestones achieved during the period. Watch the full webinar replay to hear more about the
- [H1 FY26 Investor Presentation](https://pharmx.com.au/resource/h1-fy26-investor-presentation/)
- [H1 FY26 Results Announcement](https://pharmx.com.au/resource/h1-fy26-results-announcement/)
- [Half Yearly Reports & Accounts](https://pharmx.com.au/resource/half-yearly-reports-accounts/)
- [Proposed issue of securities - PHX](https://pharmx.com.au/resource/proposed-issue-of-securities-phx/)
- [Pharmx and Sigma enter multi-year strategic alliance](https://pharmx.com.au/resource/pharmx-and-sigma-enter-multi-year-strategic-alliance/)
- [Notice of Results Announcement - 31 December 2025](https://pharmx.com.au/resource/notice-of-results-announcement-31-december-2025/)
- [Pharmx banners for print collateral](https://pharmx.com.au/resource/supplier-toolkit-banners-for-flyers/) - At Pharmx, we believe in empowering our suppliers to maximise their sales potential. By leveraging your customer networks and using our suite of powerful assets and templates, you can drive growth, improve visibility, and increase customer loyalty. Whether you're promoting a new product or reinforcing your brand, high-quality marketing collateral can help you capture attention,
- [Pharmx-led marketing support](https://pharmx.com.au/resource/supplier-toolkit-pharmx-led-marketing-support/) - As a valued partner of the Pharmx network, you gain access to a variety of marketing initiatives designed to expand your reach across our extensive pharmacy network. Below is a snapshot of the complimentary and paid activities we provide. Complimentary Activities Supplier directory We keep our pharmacy network in the loop about all the amazing
- [Results of Annual General Meeting](https://pharmx.com.au/resource/results-of-annual-general-meeting-2/)
- [Chairman's Address & CEO Presentation](https://pharmx.com.au/resource/chairmans-address-ceo-presentation/)
- [Pharmx launches new Marketplace platform](https://pharmx.com.au/resource/pharmx-launches-new-marketplace-platform/)
- [Board Charter](https://pharmx.com.au/resource/board-charter/)
- [Notice of Annual General Meeting & Proxy Form](https://pharmx.com.au/resource/notice-of-annual-general-meeting-proxy-form-3/)
- [Update - Notification of cessation of securities - PHX](https://pharmx.com.au/resource/update-notification-of-cessation-of-securities-phx/)
- [Notification of cessation of securities - PHX](https://pharmx.com.au/resource/notification-of-cessation-of-securities-phx-2/)
- [Notification regarding unquoted securities - PHX](https://pharmx.com.au/resource/notification-regarding-unquoted-securities-phx-3/)
- [Application for quotation of securities - PHX](https://pharmx.com.au/resource/application-for-quotation-of-securities-phx-2/)
- [Update on Pharmacy Portal - StockView Feature Introduction](https://pharmx.com.au/resource/update-on-pharmacy-portal-stockview-feature-introduction/)
- [Pharmx Technologies - H1 FY25 Shareholder Webinar](https://pharmx.com.au/resource/pharmx-technologies-h1-fy25-shareholder-webinar/) - Pharmx CEO Tom Culver and CFO Jon Newbery hosted a shareholder webinar discussing H1 FY25 financial results and operational activities.
- [Pharmx FY25 Results Presentation](https://pharmx.com.au/resource/pharmx-fy25-results-presentation/) - Pharmx has released our results for the FY25 financial year, underscoring strong growth and continued investment in future innovation. Pharmx CEO Tom Culver and CFO Zoe Hillier shared the highlights, including a total FY25 revenue of $7.5 million, up 13% on the previous corresponding period (PCP), alongside strong EBITDA of $1.61 million.
- [Pharmx launches new Supplier Portal](https://pharmx.com.au/resource/pharmx-launches-new-supplier-portal-2/) - CEO Tom Culver discusses Pharmx's new Supplier Portal – allowing suppliers to reach up to 99% of ANZ pharmacies with a single login, and start trading in just one day.
- [2025 Annual General Meeting - Key Dates](https://pharmx.com.au/resource/2025-annual-general-meeting-key-dates/)
- [Pharmx at AU Microcap Conference 2024](https://pharmx.com.au/resource/pharmx-at-au-microcap-conference-2024/) - Did you know that 1 in 3 Australians see their pharmacist as their most trusted healthcare provider? With 70% saying pharmacists are the most accessible professionals in their communities, pharmacies are now stepping up as essential hubs of care—especially as Australia’s population ages and the focus on wellness continues to grow. Missed Pharmx’s insights on
- [Initial Director's Interest Notice - A Mellis](https://pharmx.com.au/resource/initial-directors-interest-notice-a-mellis/)
- [Final Director's Interest Notice - A Mellis](https://pharmx.com.au/resource/final-directors-interest-notice-a-mellis/)
- [Final Director's Interest Notice - D Bastas](https://pharmx.com.au/resource/final-directors-interest-notice-d-bastas/)
- [Director Changes & Office Address Update](https://pharmx.com.au/resource/director-changes-office-address-update/)
- [Appendix 4G & Corporate Governance Statement](https://pharmx.com.au/resource/appendix-4g-corporate-governance-statement-3/)
- [Audit and Risk Committee Charter](https://pharmx.com.au/resource/audit-and-risk-committee-charter/)
- [Omnibus Equity Plan Rules](https://pharmx.com.au/resource/omnibus-equity-plan-rules/)
- [Investor Presentation](https://pharmx.com.au/resource/investor-presentation-2/)
- [FY25 Results](https://pharmx.com.au/resource/fy25-results/)
- [Appendix 4G & Corporate Governance Statement](https://pharmx.com.au/resource/appendix-4g-corporate-governance-statement-2/)
- [2025 Annual Report](https://pharmx.com.au/resource/2025-annual-report/)
- [Appendix 4E & FY2025 Annual Report](https://pharmx.com.au/resource/appendix-4e-fy2025-annual-report/)
- [Notice of Results Announcement](https://pharmx.com.au/resource/notice-of-results-announcement-3/)
- [Reinstatement to Quotation](https://pharmx.com.au/resource/reinstatement-to-quotation/)
- [Supplementary Announcement](https://pharmx.com.au/resource/supplementary-announcement/)
- [Suspension from Quotation](https://pharmx.com.au/resource/suspension-from-quotation/)
- [Trading Halt](https://pharmx.com.au/resource/trading-halt-2/)
- [Pause in trading](https://pharmx.com.au/resource/pause-in-trading/)
- [NDSS Agreement Renewal and Supplier Growth Momentum](https://pharmx.com.au/resource/ndss-agreement-renewal-and-supplier-growth-momentum/)
- [Pharmx strengthens Gateway offering with new Pharmacy Portal](https://pharmx.com.au/resource/pharmx-strengthens-gateway-offering-with-new-pharmacy-portal/)
- [Shareholder Newsletter - May 2025](https://pharmx.com.au/resource/shareholder-newsletter-may-2025/)
- [Notification regarding unquoted securities - PHX](https://pharmx.com.au/resource/notification-regarding-unquoted-securities-phx-2/)
- [Pharmx launches new Supplier Portal](https://pharmx.com.au/resource/pharmx-launches-new-supplier-portal/)
- [Notice of ceasing to be a substantial holder](https://pharmx.com.au/resource/notice-of-ceasing-to-be-a-substantial-holder/)
- [Pharmx to present at Coffee Microcap Results Webinar](https://pharmx.com.au/resource/pharmx-to-present-at-coffee-microcap-results-webinar/)
- [H1 FY25 Shareholder Webinar (Youtube)](https://pharmx.com.au/resource/h1-fy25-shareholder-webinar-youtube/)
- [H1 FY25 Investor Presentation](https://pharmx.com.au/resource/h1-fy25-investor-presentation/)
- [H1 FY25 Results Announcement](https://pharmx.com.au/resource/h1-fy25-results-announcement/)
- [Half Yearly Report and Accounts](https://pharmx.com.au/resource/half-yearly-report-and-accounts-2/)
- [Pharmx announces strategic partnership with Toniq](https://pharmx.com.au/resource/pharmx-announces-strategic-partnership-with-toniq/)
- [Notice of Results Announcement](https://pharmx.com.au/resource/notice-of-results-announcement-2/)
- [Investor Presentation](https://pharmx.com.au/resource/investor-presentation/)
- [Notification of cessation of securities - PHX](https://pharmx.com.au/resource/notification-of-cessation-of-securities-phx/)
- [Results of Annual General Meeting](https://pharmx.com.au/resource/results-of-annual-general-meeting/)
- [Chairman's Address & AGM Presentation](https://pharmx.com.au/resource/chairmans-address-agm-presentation/)
- [Change of Company Secretary](https://pharmx.com.au/resource/change-of-company-secretary/)
- [Update on Fred Appeals in Legal Proceedings](https://pharmx.com.au/resource/update-on-fred-appeals-in-legal-proceedings/)
- [Letter to Shareholders](https://pharmx.com.au/resource/letter-to-shareholders/)
- [Delay of Results Announcement](https://pharmx.com.au/resource/delay-of-results-announcement/)
- [FY24 Results](https://pharmx.com.au/resource/fy24-results/)
- [2024 Annual Report and Appendix 4E](https://pharmx.com.au/resource/2024-annual-report-and-appendix-4e/)
- [Alternate Director](https://pharmx.com.au/resource/alternate-director/)
- [Initial Director's Interest Notice](https://pharmx.com.au/resource/initial-directors-interest-notice-2/)
- [Notice of Annual General Meeting/Proxy Form](https://pharmx.com.au/resource/notice-of-annual-general-meeting-proxy-form/)
- [Notice of Results Announcement](https://pharmx.com.au/resource/notice-of-results-announcement/)
- [Notification regarding unquoted securities - PHX](https://pharmx.com.au/resource/notification-regarding-unquoted-securities-phx/)
- [ATO confirms tax implications of return of share capital](https://pharmx.com.au/resource/ato-confirms-tax-implications-of-return-of-share-capital/)
- [Notice of Results Announcement 30 June 2024](https://pharmx.com.au/resource/notice-of-results-announcement-30-june-2024/)
- [Change in substantial shareholding from AEF](https://pharmx.com.au/resource/change-in-substantial-shareholding-from-aef/)
- [Ceasing to be a substantial shareholder from AEF](https://pharmx.com.au/resource/ceasing-to-be-a-substantial-shareholder-from-aef/)
- [Update Fred Appeal legal proceedings re Corum Systems/PharmX](https://pharmx.com.au/resource/update-fred-appeal-legal-proceedings-re-corum-systems-pharmx/)
- [Trading Halt](https://pharmx.com.au/resource/trading-halt/)
- [Response to ASX Price Query](https://pharmx.com.au/resource/response-to-asx-price-query/)
- [Change of Director's Interest Notice - N England](https://pharmx.com.au/resource/change-of-directors-interest-notice-n-england/)
- [Appointment of Interim CFO and change of Company Secretary](https://pharmx.com.au/resource/appointment-of-interim-cfo-and-change-of-company-secretary/)
- [Results Release and Investor Presentation](https://pharmx.com.au/resource/results-release-and-investor-presentation/)
- [Application for quotation of securities - PHX](https://pharmx.com.au/resource/application-for-quotation-of-securities-phx/)
- [Appointment of Chief Executive Officer](https://pharmx.com.au/resource/appointment-of-chief-executive-officer/)
- [Results of Meeting](https://pharmx.com.au/resource/results-of-meeting/)
- [Chair's Address to Shareholders](https://pharmx.com.au/resource/chairs-address-to-shareholders/)
- [Return of Capital - PHX](https://pharmx.com.au/resource/return-of-capital-phx/)
- [Capital Return Confirmation](https://pharmx.com.au/resource/capital-return-confirmation/)
- [Half Yearly Report and Accounts](https://pharmx.com.au/resource/half-yearly-report-and-accounts/)
- [Half-Year Report Investor Update](https://pharmx.com.au/resource/half-year-report-investor-update/)
- [Corum announces expected non-cash impairment](https://pharmx.com.au/resource/corum-announces-expected-non-cash-impairment/)
- [Appendix 4E and Annual Accounts](https://pharmx.com.au/resource/appendix-4e-and-annual-accounts/)
- [Chairman and CEO Address to Shareholders](https://pharmx.com.au/resource/chairman-and-ceo-address-to-shareholders/)
- [Corum signs up to My Health Record](https://pharmx.com.au/resource/corum-signs-up-to-my-health-record/)
- [Completion of sale of pharmacy software business](https://pharmx.com.au/resource/completion-of-sale-of-pharmacy-software-business/)
- [Change of Company Name](https://pharmx.com.au/resource/change-of-company-name/)
- [Appointment of Executive Director](https://pharmx.com.au/resource/appointment-of-executive-director/)
- [Suspension from Official Quotation](https://pharmx.com.au/resource/suspension-from-official-quotation/)
- [Reinstatement to Official Quotation](https://pharmx.com.au/resource/reinstatement-to-official-quotation/)
- [Company Update](https://pharmx.com.au/resource/company-update/)
- [Chief Executive Officer Appointment](https://pharmx.com.au/resource/chief-executive-officer-appointment/)
- [Appendix 4G - Corporate Governance](https://pharmx.com.au/resource/appendix-4g-corporate-governance/)
- [FY15 Company Presentation](https://pharmx.com.au/resource/fy15-company-presentation/)
- [FY15 Results Announcement](https://pharmx.com.au/resource/fy15-results-announcement/)
- [Preliminary Final Report](https://pharmx.com.au/resource/preliminary-final-report/)
- [Appendix 4G - Key to Corporate Governance Disclosures](https://pharmx.com.au/resource/appendix-4g-key-to-corporate-governance-disclosures/)
- [Managing Director / CEO Resignation](https://pharmx.com.au/resource/managing-director-ceo-resignation/)
- [Director Appointment/Resignation](https://pharmx.com.au/resource/director-appointment-resignation/)
- [Appendix 3B - Exercise of Performance Rights](https://pharmx.com.au/resource/appendix-3b-exercise-of-performance-rights/)
- [Annual Report to shareholders](https://pharmx.com.au/resource/annual-report-to-shareholders/)
- [Managing Director / CEO appointments and contract terms](https://pharmx.com.au/resource/managing-director-ceo-appointments-and-contract-terms/)
- [Appendix 3B - Employee Share Scheme](https://pharmx.com.au/resource/appendix-3b-employee-share-scheme/)
- [Details of Company Address](https://pharmx.com.au/resource/details-of-company-address/)
- [Director Resignation](https://pharmx.com.au/resource/director-resignation/)
- [Company Secretary Appointment](https://pharmx.com.au/resource/company-secretary-appointment/)
- [Response to ASX Query](https://pharmx.com.au/resource/response-to-asx-query/)
- [Acting MD / CEO - Terms of Appointment](https://pharmx.com.au/resource/acting-md-ceo-terms-of-appointment/)
- [Appendix 4C - quarterly and commentary](https://pharmx.com.au/resource/appendix-4c-quarterly-and-commentary/)
- [Director Appointment / Company Secretary Resignation](https://pharmx.com.au/resource/director-appointment-company-secretary-resignation/)
- [Chairman and Director Appointments](https://pharmx.com.au/resource/chairman-and-director-appointments/)
- [Performance Rights Lapse](https://pharmx.com.au/resource/performance-rights-lapse/)
- [Chairman's Address to Shareholders](https://pharmx.com.au/resource/chairmans-address-to-shareholders-2/)
- [Appendix 3B - exercise of options](https://pharmx.com.au/resource/appendix-3b-exercise-of-options/)
- [Expiry of Employee Share Options](https://pharmx.com.au/resource/expiry-of-employee-share-options/)
- [Dividend Declaration](https://pharmx.com.au/resource/dividend-declaration/)
- [Change in Managing Director / Chief Executive Officer](https://pharmx.com.au/resource/change-in-managing-director-chief-executive-officer/)
- [FY23 Appendix 4E and Annual Report](https://pharmx.com.au/resource/fy23-appendix-4e-and-annual-report/)
- [FY23 Results Announcement](https://pharmx.com.au/resource/fy23-results-announcement/)
- [FY23 Results Investor Presentation](https://pharmx.com.au/resource/fy23-results-investor-presentation/)
- [Results of General Meeting](https://pharmx.com.au/resource/results-of-general-meeting/)
- [Further Update on Legal Proceedings](https://pharmx.com.au/resource/further-update-on-legal-proceedings/)
- [Sale of Corum Pharmacy Software Business](https://pharmx.com.au/resource/sale-of-corum-pharmacy-software-business/)
- [Change of Registered Office](https://pharmx.com.au/resource/change-of-registered-office/)
- [Notice of Extraordinary General MeetingProxy Form](https://pharmx.com.au/resource/notice-of-extraordinary-general-meetingproxy-form/)
- [Investor Presentation FY22](https://pharmx.com.au/resource/investor-presentation-fy22/)
- [Key AGM Dates](https://pharmx.com.au/resource/key-agm-dates/)
- [Notice of Annual General Meeting and Proxy Form](https://pharmx.com.au/resource/notice-of-annual-general-meeting-and-proxy-form/)
- [Application for quotation of securities](https://pharmx.com.au/resource/application-for-quotation-of-securities/)
- [Chair’s Presentation to the AGM](https://pharmx.com.au/resource/chairs-presentation-to-the-agm/)
- [Amendment to the Constitution](https://pharmx.com.au/resource/amendment-to-the-constitution/)
- [Update on Legal Proceedings](https://pharmx.com.au/resource/update-on-legal-proceedings/)
- [Final Director’s Interest Notice - J Sallabank](https://pharmx.com.au/resource/final-directors-interest-notice-j-sallabank/)
- [Symbion & ProPharma sign long term PharmX agreement](https://pharmx.com.au/resource/symbion-propharma-sign-long-term-pharmx-agreement/)
- [PharmX Agreement - Supplementary Information](https://pharmx.com.au/resource/pharmx-agreement-supplementary-information/)
- [H1 FY22 Interim Media Release and Results Presentation](https://pharmx.com.au/resource/h1-fy22-interim-media-release-and-results-presentation/)
- [Corum completes sale of Real Estate eCommerce business unit](https://pharmx.com.au/resource/corum-completes-sale-of-real-estate-ecommerce-business-unit/)
- [Sigma signs long term PharmX agreement](https://pharmx.com.au/resource/sigma-signs-long-term-pharmx-agreement/)
- [PharmX Launches PharmXchange Platform](https://pharmx.com.au/resource/pharmx-launches-pharmxchange-platform/)
- [FY22 Results Release](https://pharmx.com.au/resource/fy22-results-release/)
- [Trading Update](https://pharmx.com.au/resource/trading-update/)
- [Corum Agrees Sale of eCommerce Business Unit](https://pharmx.com.au/resource/corum-agrees-sale-of-ecommerce-business-unit/)
- [Resignation of Managing Director](https://pharmx.com.au/resource/resignation-of-managing-director/)
- [Notification regarding unquoted securities - COO](https://pharmx.com.au/resource/notification-regarding-unquoted-securities-coo/)
- [Notice of Results Announcement and Investor Presentation](https://pharmx.com.au/resource/notice-of-results-announcement-and-investor-presentation/)
- [Press Release and Investor Presentation](https://pharmx.com.au/resource/press-release-and-investor-presentation/)
- [Corum extends relationship with Sigma into WholeLife](https://pharmx.com.au/resource/corum-extends-relationship-with-sigma-into-wholelife/)
- [2021 Annual General Meeting Key Dates](https://pharmx.com.au/resource/2021-annual-general-meeting-key-dates/)
- [Notice of General Meeting/Proxy Form](https://pharmx.com.au/resource/notice-of-general-meeting-proxy-form-2/)
- [Corum Trading Update](https://pharmx.com.au/resource/corum-trading-update/)
- [Key Retail Pharmacy Groups signed on to drive PharmX growth](https://pharmx.com.au/resource/key-retail-pharmacy-groups-signed-on-to-drive-pharmx-growth/)
- [Chairman & CEO Address and AGM Presentation](https://pharmx.com.au/resource/chairman-ceo-address-and-agm-presentation/)
- [Update on Legal Proceedings relating to PharmX](https://pharmx.com.au/resource/update-on-legal-proceedings-relating-to-pharmx/)
- [Change of Director’s Interest Notice Newbery](https://pharmx.com.au/resource/change-of-directors-interest-notice-newbery/)
- [HY 21 Reporting Date and Investor Presentation](https://pharmx.com.au/resource/hy-21-reporting-date-and-investor-presentation/)
- [H1 FY21 Interim Media Release and Results Presentation](https://pharmx.com.au/resource/h1-fy21-interim-media-release-and-results-presentation/)
- [Quarterly Activities Report and Appendix 4C](https://pharmx.com.au/resource/quarterly-activities-report-and-appendix-4c/)
- [Change of Share Registry](https://pharmx.com.au/resource/change-of-share-registry/)
- [Update on Legal Proceedings14 May 2021](https://pharmx.com.au/resource/update-on-legal-proceedings14-may-2021/)
- [Quarterly Activity Report and Appendix 4C](https://pharmx.com.au/resource/quarterly-activity-report-and-appendix-4c/)
- [Notification of cessation of securities - COO](https://pharmx.com.au/resource/notification-of-cessation-of-securities-coo/)
- [CEO’s Address to Shareholders](https://pharmx.com.au/resource/ceos-address-to-shareholders/)
- [Appointment of Dennis Bastas as Director](https://pharmx.com.au/resource/appointment-of-dennis-bastas-as-director/)
- [Becoming a substantial holder Bastas](https://pharmx.com.au/resource/becoming-a-substantial-holder-bastas/)
- [Initial Director’s Interest Notice Bastas](https://pharmx.com.au/resource/initial-directors-interest-notice-bastas/)
- [Change of Director’s Interest Notice Shaw](https://pharmx.com.au/resource/change-of-directors-interest-notice-shaw/)
- [Completion of $5.6m Capital Raising](https://pharmx.com.au/resource/completion-of-5-6m-capital-raising/)
- [2020 Annual General Meeting Update](https://pharmx.com.au/resource/2020-annual-general-meeting-update/)
- [Becoming a substantial holder from AEF](https://pharmx.com.au/resource/becoming-a-substantial-holder-from-aef/)
- [Jayne Shaw Joins Corum Board](https://pharmx.com.au/resource/jayne-shaw-joins-corum-board/)
- [Appendix 2A](https://pharmx.com.au/resource/appendix-2a/)
- [Arrotex Pharmaceuticals becomes strategic shareholder](https://pharmx.com.au/resource/arrotex-pharmaceuticals-becomes-strategic-shareholder/)
- [Cleansing Notice](https://pharmx.com.au/resource/cleansing-notice/)
- [Release of ordinary shares from escrow](https://pharmx.com.au/resource/release-of-ordinary-shares-from-escrow/)
- [Chairman’s Address to Shareholders](https://pharmx.com.au/resource/chairmans-address-to-shareholders/)
- [Investor Presentation September 2020](https://pharmx.com.au/resource/investor-presentation-september-2020/)
- [Corum Announces Completion of PharmX Acquisition](https://pharmx.com.au/resource/corum-announces-completion-of-pharmx-acquisition/)
- [Appendix 3Z Final Director’s Interest](https://pharmx.com.au/resource/appendix-3z-final-directors-interest/)
- [Update - Proposed issue of Securities](https://pharmx.com.au/resource/update-proposed-issue-of-securities/)
- [Despatch of Offer Booklet](https://pharmx.com.au/resource/despatch-of-offer-booklet/)
- [Indicative Timetable of Key Dates](https://pharmx.com.au/resource/indicative-timetable-of-key-dates/)
- [Entitlement Offer - Extension of Closing date](https://pharmx.com.au/resource/entitlement-offer-extension-of-closing-date/)
- [Corum Executive Management Changes](https://pharmx.com.au/resource/corum-executive-management-changes/)
- [Acquisition of Remaining 57% interest in PharmX](https://pharmx.com.au/resource/acquisition-of-remaining-57-interest-in-pharmx/)
- [Offer Booklet](https://pharmx.com.au/resource/offer-booklet/)
- [Entitlement Offer Letter to Ineligible Shareholders](https://pharmx.com.au/resource/entitlement-offer-letter-to-ineligible-shareholders/)
- [Cleansing Statement](https://pharmx.com.au/resource/cleansing-statement/)
- [Corum New Company Secretary Appointment](https://pharmx.com.au/resource/corum-new-company-secretary-appointment/)
- [Proposed issue of Securities - COO](https://pharmx.com.au/resource/proposed-issue-of-securities-coo/)
- [Director Resignation and Final Directors Interest Notice](https://pharmx.com.au/resource/director-resignation-and-final-directors-interest-notice/)
- [Corum to increase ownership in PharmX](https://pharmx.com.au/resource/corum-to-increase-ownership-in-pharmx/)
- [Director Resignation and Final Director’s Interest Notice](https://pharmx.com.au/resource/director-resignation-and-final-directors-interest-notice-2/)
- [Change of Auditor - Audit Practice Restructure](https://pharmx.com.au/resource/change-of-auditor-audit-practice-restructure/)
- [Appendix 3B - Performance Rights Issues](https://pharmx.com.au/resource/appendix-3b-performance-rights-issues/)
- [Corum Group Annual Report 2020](https://pharmx.com.au/resource/corum-group-annual-report-2020/)
- [Appendix 4G & Corporate Governance Statement](https://pharmx.com.au/resource/appendix-4g-corporate-governance-statement/)
- [Update on BAMM Agreement](https://pharmx.com.au/resource/update-on-bamm-agreement/)
- [Change of Director’s Interest Notice](https://pharmx.com.au/resource/change-of-directors-interest-notice/)
- [Management Incentive Plan](https://pharmx.com.au/resource/management-incentive-plan/)
- [Chairman Retirement](https://pharmx.com.au/resource/chairman-retirement/)
- [Final Director’s Interest Notice](https://pharmx.com.au/resource/final-directors-interest-notice/)
- [Change in substantial holding](https://pharmx.com.au/resource/change-in-substantial-holding/)
- [Cleansing Statement Section708A(5)€](https://pharmx.com.au/resource/cleansing-statement-section708a5e/)
- [Completion of Share Placement](https://pharmx.com.au/resource/completion-of-share-placement/)
- [Investor Group Substantial shareholder notice 603](https://pharmx.com.au/resource/investor-group-substantial-shareholder-notice-603/)
- [Board Succession](https://pharmx.com.au/resource/board-succession/)
- [Ceasing to be a substantial holder](https://pharmx.com.au/resource/ceasing-to-be-a-substantial-holder/)
- [Update on Court Proceedings](https://pharmx.com.au/resource/update-on-court-proceedings/)
- [Director Appointment](https://pharmx.com.au/resource/director-appointment/)
- [Appendix 4C Quarterly](https://pharmx.com.au/resource/appendix-4c-quarterly-2/)
- [Addendum to Notice of Annual General Meeting](https://pharmx.com.au/resource/addendum-to-notice-of-annual-general-meeting/)
- [Waiver From Listing Rule 7.3.2](https://pharmx.com.au/resource/waiver-from-listing-rule-7-3-2/)
- [Chairman’s Address](https://pharmx.com.au/resource/chairmans-address/)
- [Ceasing to be Substantial shareholder notice change 605](https://pharmx.com.au/resource/ceasing-to-be-substantial-shareholder-notice-change-605/)
- [AGM Results Poll](https://pharmx.com.au/resource/agm-results-poll/)
- [Appendix 3B - Capital Raise](https://pharmx.com.au/resource/appendix-3b-capital-raise/)
- [Initial director’s Interest Notice](https://pharmx.com.au/resource/initial-directors-interest-notice/)
- [Substantial holder notice](https://pharmx.com.au/resource/substantial-holder-notice/)
- [Corum secures strategic partnership](https://pharmx.com.au/resource/corum-secures-strategic-partnership/)
- [Directorship](https://pharmx.com.au/resource/directorship/)
- [Notice of Annual General Meeting & Proxy Form](https://pharmx.com.au/resource/notice-of-annual-general-meeting-proxy-form-2/)
- [Notice of EGM / Proxy Form](https://pharmx.com.au/resource/notice-of-egm-proxy-form/)
- [Half Yearly Results and Accounts](https://pharmx.com.au/resource/half-yearly-results-and-accounts/)
- [Half Yearly Results Announcement](https://pharmx.com.au/resource/half-yearly-results-announcement/)
- [Results of EGM](https://pharmx.com.au/resource/results-of-egm/)
- [SaaS technolgy collaboration agreement](https://pharmx.com.au/resource/saas-technolgy-collaboration-agreement/)
- [Corum structured for growth](https://pharmx.com.au/resource/corum-structured-for-growth/)
- [Appendix 4E and Annual Report](https://pharmx.com.au/resource/appendix-4e-and-annual-report/)
- [Appendix 4G and Corporate Governance Statement](https://pharmx.com.au/resource/appendix-4g-and-corporate-governance-statement/)
- [Notice of General Meeting / Proxy Form](https://pharmx.com.au/resource/notice-of-general-meeting-proxy-form/)
- [Corum Clear Update](https://pharmx.com.au/resource/corum-clear-update/)
- [Appendix 4E Preliminary final report](https://pharmx.com.au/resource/appendix-4e-preliminary-final-report/)
- [AGM Chair and CEO Address](https://pharmx.com.au/resource/agm-chair-and-ceo-address/)
- [EGM ASX Waiver](https://pharmx.com.au/resource/egm-asx-waiver/)
- [Corum Clear Dispense Update](https://pharmx.com.au/resource/corum-clear-dispense-update/)
- [Notice of Annual General Meeting and Explanatory Memorandum](https://pharmx.com.au/resource/notice-of-annual-general-meeting-and-explanatory-memorandum/)
- [Appendix 4C - quarterly](https://pharmx.com.au/resource/appendix-4c-quarterly/)
- [Annual Reports #1](https://pharmx.com.au/resource/annual-reports-1/)
- [Select Notice of Annual General Meeting/Proxy Form](https://pharmx.com.au/resource/select-notice-of-annual-general-meeting-proxy-form/)
- [Announcement 2](https://pharmx.com.au/resource/announcement-2/)
- [Announcement 1](https://pharmx.com.au/resource/announcement-1/)
- [2024 Annual Report](https://pharmx.com.au/resource/2024-annual-report/)
- [Notice of Rights of Members in connection with certain documents – Corporations Act 2001 S110K](https://pharmx.com.au/resource/notice-of-rights-of-members-in-connection-with-certain-documents-corporations-act-2001-s110k/)
- [Company Constitution](https://pharmx.com.au/resource/company-constitution/)
- [Remuneration and Nomination Committee Charter](https://pharmx.com.au/resource/remuneration-and-nomination-committee-charter/)
- [Corporate Code of Conduct](https://pharmx.com.au/resource/corporate-code-of-conduct/)
- [Anti-Bribery and Corruption Policy](https://pharmx.com.au/resource/anti-bribery-and-corruption-policy/)
- [Market Disclosure Policy](https://pharmx.com.au/resource/market-disclosure-policy/)
- [Diversity and Inclusion Policy](https://pharmx.com.au/resource/diversity-and-inclusion-policy/)
- [Corporate Security Trading Policy](https://pharmx.com.au/resource/corporate-security-trading-policy/)
- [Whistleblower Policy](https://pharmx.com.au/resource/whistleblower-policy/)
- [Conflict of Interest Policy](https://pharmx.com.au/resource/conflict-of-interest-policy/)
- [2023 Annual Report](https://pharmx.com.au/resource/2023-annual-report/)
- [2022 Annual Report](https://pharmx.com.au/resource/2022-annual-report/)
- [2021 Annual Report](https://pharmx.com.au/resource/2021-annual-report/)
- [2019 Annual Report](https://pharmx.com.au/resource/2019-annual-report/)
- [2020 Annual Report](https://pharmx.com.au/resource/2020-annual-report/)
- [2015 Annual Report](https://pharmx.com.au/resource/2015-annual-report/)
- [2017 Annual Report](https://pharmx.com.au/resource/2017-annual-report/)
- [2018 Annual Report](https://pharmx.com.au/resource/2018-annual-report/)
- [2011 Annual Report](https://pharmx.com.au/resource/2011-annual-report/)
- [2012 Annual Report](https://pharmx.com.au/resource/2012-annual-report/)
- [2013 Annual Report](https://pharmx.com.au/resource/2013-annual-report/)
- [2014 Annual Report](https://pharmx.com.au/resource/2014-annual-report/)
- [2007 Annual Report](https://pharmx.com.au/resource/2007-annual-report/)
- [2008 Annual Report](https://pharmx.com.au/resource/2008-annual-report/)
- [2009 Annual Report](https://pharmx.com.au/resource/2009-annual-report/)
- [2010 Annual Report](https://pharmx.com.au/resource/2010-annual-report/)
- [2003 Annual Report](https://pharmx.com.au/resource/2003-annual-report/)
- [2004 Annual Report](https://pharmx.com.au/resource/2004-annual-report/)
- [2005 Annual Report](https://pharmx.com.au/resource/2005-annual-report/)
- [2006 Annual Report](https://pharmx.com.au/resource/2006-annual-report/)
- [2002 Annual Report](https://pharmx.com.au/resource/2002-annual-report/)

## Resource Types

- [Corporate Governance](https://pharmx.com.au/resource-type/corporate-governance/)
- [Annual Reports](https://pharmx.com.au/resource-type/annual-report/)
- [Announcements](https://pharmx.com.au/resource-type/announcement/)
- [Articles](https://pharmx.com.au/resource-type/articles/)
- [Videos](https://pharmx.com.au/resource-type/videos/)
- [Supplier Toolkit](https://pharmx.com.au/resource-type/supplier-toolkit/)